Status:
TERMINATED
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918
Lead Sponsor:
AstraZeneca
Conditions:
Cancer,
Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD6918 based on the side effects experienced by patients with advanced solid malign...
Eligibility Criteria
Inclusion
- Advanced solid tumors for which standard treatment does not exist or is no longer effective.
- For chemotherapy combination treatment, must be suitable for treatment with either gemcitabine or pemetrexed.
- Relatively good overall health other than cancer.
Exclusion
- Poor bone marrow function (not producing enough blood cells).
- Poor liver or kidney function.
- Serious heart conditions
- History of uncontrolled epilepsy, Parkinson's disease, Alzheimer's disease, brain tumor or any uncontrolled psychiatric or nervous system condition
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2009
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00733031
Start Date
August 1 2008
End Date
March 1 2009
Last Update
December 10 2010
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aurora, Colorado, United States
2
Research Site
Nashville, Tennessee, United States